Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from leukemia, lymphoma & multiple myeloma.
Therapy developed by IIT-Bombay spin-off company ImmunoACT approved for relapsed-refractory B-cell lymphoma, leukemia, to be available in around 20 govt & pvt hospitals across major cities.
Pharma giant Bristol Myers Squibb & partner 2seventy bio say they've successfully tested the treatment, which is aimed at stimulating patient’s immune system to act more efficiently.
Forget comparing it with classics like Hrithik’s Ek Pal Ka Jeena or the slick title track of Dhoom 2, Janaab-e-Aali does not even come close to Ghungroo.
India’s industrial output growth saw a 10-month low in June, with Index of Industrial Production (IIP) growing by mere 1.5% as against 1.9% in May 2025.
Standing up to America is usually not a personal risk for a leader in India. Any suggestions of foreign pressure unites India behind who they see as leading them in that fight.
COMMENTS